Marta Milo

Marta Milo

Auto-generated profile, based on publicly available information

Marta Milo

Oncology R&D, AstraZeneca, Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
OTOliver Thompson
Oliver Thompson
FMFerdinand von Meyenn
Ferdinand von Meyenn
ZHZoe Hewitt
Zoe Hewitt
JAJohn Alexander
John Alexander
AWAndrew Wood
Andrew Wood
PAPeter W. Andrews
Peter W. Andrews
The occurrence of repetitive genomic changes that provide a selective growth advantage in pluripotent stem cells is of concern for their clinical application. However, the effect of different culture conditions on the underlying mutation rate is unknown. Here we show that the mutation rate in two human embryonic stem cell lines derived and banked for clinical application is low and not substantially affected by culture with Rho Kinase inhibitor, commonly used in their routine maintenance. However, the mutation rate is reduced by >50% in cells cultured under 5% oxygen, when we also found alterations in imprint methylation and reversible DNA hypomethylation. Mutations are evenly distributed across the chromosomes, except for a slight increase on the X-chromosome, and an elevation in intergenic regions suggesting that chromatin structure may affect mutation rate. Overall the results suggest that pluripotent stem cells are not subject to unusually high rates of genetic or epigenetic alterations.

9 July 2009 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
RPRichard D Pearson
Richard D Pearson
XLXuejun Liu
Xuejun Liu
GSGuido Sanguinetti
Guido Sanguinetti
MMMarta Milo
Marta Milo
NLNeil Lawrence
Neil Lawrence
MRMagnus Rattray
Magnus Rattray
Most analyses of microarray data are based on point estimates of expression levels and ignore the uncertainty of such estimates. By determining uncertainties from Affymetrix GeneChip data and propagating these uncertainties to downstream analyses it has been shown that we can improve results of differential expression detection, principal component analysis and clustering. Previously, implementations of these uncertainty propagation methods have only been available as separate packages, written in different languages. Previous implementations have also suffered from being very costly to compute, and in the case of differential expression detection, have been limited in the experimental designs to which they can be applied.

8 March 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ABAzadeh C. Bashi
Azadeh C. Bashi
ECElizabeth A. Coker
Elizabeth A. Coker
KBKrishna C. Bulusu
Krishna C. Bulusu
PJPatricia Jaaks
Patricia Jaaks
CCClaire Crafter
Claire Crafter
MGMathew J. Garnett
Mathew J. Garnett
Oncology drug combinations can improve therapeutic responses and increase treatment options for patients. The number of possible combinations is vast and responses can be context-specific. Systematic screens can identify clinically relevant, actionable combinations in defined patient subtypes. We present data for 109 anticancer drug combinations from AstraZeneca's oncology small molecule portfolio screened in 755 pan-cancer cell lines. Combinations were screened in a 7 × 7 concentration matrix, with more than 4 million measurements of sensitivity, producing an exceptionally data-rich resource. We implement a new approach using combination Emax (viability effect) and highest single agent (HSA) to assess combination benefit. We designed a clinical translatability workflow to identify combinations with clearly defined patient populations, rationale for tolerability based on tumor type and combination-specific “emergent” biomarkers, and exposures relevant to clinical doses. We describe three actionable combinations in defined cancer types, confirmed in vitro and in vivo, with a focus on hematologic cancers and apoptotic targets. Significance: We present the largest cancer drug combination screen published to date with 7 × 7 concentration response matrices for 109 combinations in more than 750 cell lines, complemented by multi-omics predictors of response and identification of “emergent” combination biomarkers. We prioritize hits to optimize clinical translatability, and experimentally validate novel combination hypotheses. This article is featured in Selected Articles from This Issue, p. 695


1 December 2003 in Biochemical Society Transactions
Verified
Journal Article
Closed access
MMM. Milo
M. Milo
Alireza FazeliAlireza Fazeli
Alireza Fazeli
MNM. Niranjan
M. Niranjan
NLNeil Lawrence
Neil Lawrence
In this work we present a probabilistic model to estimate summaries of Affymetrix GeneChip probe level data. Comparisons with two different models were made both on a publicly available dataset and on a study performed in our laboratory, showing that our model performs better for consistency of fold change.

1 March 2006 in Briefings in Bioinformatics
Verified
Journal Article
Open access
PDF file
MRMagnus Rattray
Magnus Rattray
XLXuejun Liu
Xuejun Liu
GSGuido Sanguinetti
Guido Sanguinetti
MMMarta Milo
Marta Milo
NLNeil Lawrence
Neil Lawrence
Microarray technology is associated with many sources of experimental uncertainty. In this review we discuss a number of approaches for dealing with this uncertainty in the processing of data from microarray experiments. We focus here on the analysis of high-density oligonucleotide arrays, such as the popular Affymetrix GeneChip® array, which contain multiple probes for each target. This set of probes can be used to determine an estimate for the target concentration and can also be used to determine the experimental uncertainty associated with this measurement. This measurement uncertainty can then be propagated through the downstream analysis using probabilistic methods. We give examples showing how these credibility intervals can be used to help identify differential expression, to combine information from replicated experiments and to improve the performance of principal component analysis.